OBJECTIVES: To assess paediatric antiretroviral treatment (ART) outcomes and their associations from a collaborative cohort representing 20% of the South African national treatment programme. DESIGN AND SETTING: Multi-cohort study of 7 public sector paediatric ART programmes in Gauteng, Western Cape and KwaZulu-Natal provinces. SUBJECTS: ART-naive children (< or = 16 years) who commenced treatment with > or = 3 antiretroviral drugs before March 2008. OUTCOME MEASURES: Time to death or loss to follow-up were assessed using the Kaplan-Meier method. Associations between baseline characteristics and mortality were assessed with Cox proportional hazards models stratified by site. Immune status, virological suppression and growth were described in relation to duration of ART. RESULTS: The median (interquartile range) age of 6 078 children with 9 368 child-years of follow-up was 43 (15 - 83) months, with 29% being < 18 months. Most were severely ill at ART initiation. More than 75% of children were appropriately monitored at 6-monthly intervals with viral load suppression (< 400 copies/ml) being 80% or above throughout 36 months of treatment. Mortality and retention in care at 3 years were 7.7% (95% confidence interval 7.0 - 8.6%) and 81.4% (80.1 - 82.6%), respectively. Together with young age, all markers of disease severity (low weight-for-age z-score, high viral load, severe immune suppression, stage 3/4 disease and anaemia) were independently associated with mortality. CONCLUSIONS: Dramatic clinical benefit for children accessing the national ART programme is demonstrated. Higher mortality in infants and those with advanced disease highlights the need for early diagnosis of HIV infection and commencement of ART.
OBJECTIVES: To assess paediatric antiretroviral treatment (ART) outcomes and their associations from a collaborative cohort representing 20% of the South African national treatment programme. DESIGN AND SETTING: Multi-cohort study of 7 public sector paediatric ART programmes in Gauteng, Western Cape and KwaZulu-Natal provinces. SUBJECTS:ART-naive children (< or = 16 years) who commenced treatment with > or = 3 antiretroviral drugs before March 2008. OUTCOME MEASURES: Time to death or loss to follow-up were assessed using the Kaplan-Meier method. Associations between baseline characteristics and mortality were assessed with Cox proportional hazards models stratified by site. Immune status, virological suppression and growth were described in relation to duration of ART. RESULTS: The median (interquartile range) age of 6 078 children with 9 368 child-years of follow-up was 43 (15 - 83) months, with 29% being < 18 months. Most were severely ill at ART initiation. More than 75% of children were appropriately monitored at 6-monthly intervals with viral load suppression (< 400 copies/ml) being 80% or above throughout 36 months of treatment. Mortality and retention in care at 3 years were 7.7% (95% confidence interval 7.0 - 8.6%) and 81.4% (80.1 - 82.6%), respectively. Together with young age, all markers of disease severity (low weight-for-age z-score, high viral load, severe immune suppression, stage 3/4 disease and anaemia) were independently associated with mortality. CONCLUSIONS: Dramatic clinical benefit for children accessing the national ART programme is demonstrated. Higher mortality in infants and those with advanced disease highlights the need for early diagnosis of HIV infection and commencement of ART.
Authors: Winstone M Nyandiko; Samuel Ayaya; Esther Nabakwe; Constance Tenge; John E Sidle; Constantin T Yiannoutsos; Beverly Musick; Kara Wools-Kaloustian; William M Tierney Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: Daniel P O'Brien; Delphine Sauvageot; David Olson; Myrto Schaeffer; Pierre Humblet; Mar Pudjades; Tom Ellman; Rony Zachariah; Elisabeth Szumilin; Line Arnould; Tony Read Journal: Clin Infect Dis Date: 2007-03-28 Impact factor: 9.079
Authors: Carolyn Bolton-Moore; Mwangelwa Mubiana-Mbewe; Ronald A Cantrell; Namwinga Chintu; Elizabeth M Stringer; Benjamin H Chi; Moses Sinkala; Chipepo Kankasa; Craig M Wilson; Catherine M Wilfert; Albert Mwango; Jens Levy; Elaine J Abrams; Marc Bulterys; Jeffrey S A Stringer Journal: JAMA Date: 2007-10-24 Impact factor: 56.272
Authors: Ali Judd; Katja Doerholt; Pat A Tookey; Mike Sharland; Andrew Riordan; Esse Menson; Vas Novelli; E G Hermione Lyall; Janet Masters; Gareth Tudor-Williams; Trinh Duong; Di M Gibb Journal: Clin Infect Dis Date: 2007-08-27 Impact factor: 9.079
Authors: Anand Reddi; Sarah C Leeper; Anneke C Grobler; Rosemary Geddes; K Holly France; Gillian L Dorse; Willem J Vlok; Mbali Mntambo; Monty Thomas; Kristy Nixon; Helga L Holst; Quarraisha Abdool Karim; Nigel C Rollins; Hoosen M Coovadia; Janet Giddy Journal: BMC Pediatr Date: 2007-03-17 Impact factor: 2.125
Authors: Wendy Mphatswe; Natasha Blanckenberg; Gareth Tudor-Williams; Andrew Prendergast; Christina Thobakgale; Nompumelelo Mkhwanazi; Noel McCarthy; Bruce D Walker; Photini Kiepiela; Philip Goulder Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Luisa Salazar-Vizcaya; Olivia Keiser; Mary-Ann Davies; Andreas D Haas; Nello Blaser; Vivian Cox; Brian Eley; Helena Rabie; Harry Moultrie; Janet Giddy; Robin Wood; Matthias Egger; Janne Estill Journal: AIDS Date: 2014-10-23 Impact factor: 4.177
Authors: Mary-Ann Davies; Andrew Boulle; Brian Eley; Harry Moultrie; Karl Technau; Helena Rabie; Gilles van Cutsem; Janet Giddy; Robin Wood; Matthias Egger; Olivia Keiser Journal: Trop Med Int Health Date: 2011-08-11 Impact factor: 2.622
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196